Tabernero, Josep; Taieb, Julien; Prager, Gerald W.; Ciardiello, Fortunato; Fakih, Marwan; Leger, Catherine; Fougeray, Ronan; Amellal, Nadia; van Cutsem, Eric published an article in 2021, the title of the article was Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.Related Products of 65-71-4 And the article contains the following content:
Preliminary studies of FTD/TPI plus bevacizumab have produced encouraging results in the treatment of refractory metastatic colorectal cancer. Here, we describe the design of the multinational Phase III SUNLIGHT, an open-label study of FTD/TPI plus bevacizumab as third-line treatment for patients with unresectable metastatic colorectal cancer. A total of 490 patients will be randomized 1:1 to receive either FTD/TPI plus bevacizumab, or FTD/TPI monotherapy. The primary objective is to significantly improve overall survival with FTD/TPI plus bevacizumab compared with FTD/TPI monotherapy. The first patient was enrolled in Nov. 2020. Lay abstract : Trifluridine/tipiracil is a cancer treatment used in patients with bowel cancer that has spread to other parts of the body (this is called ‘metastatic bowel cancer’). This medicine is taken by mouth. Recently, a number of studies have suggested that better results might be obtained when trifluridine/tipiracil is used in combination with another cancer drug, bevacizumab. This article describes the design of a new clin. trial. The SUNLIGHT is being set up to confirm whether the combination of trifluridine/tipiracil plus bevacizumab is indeed better than trifluridine/tipiracil alone for patients who have already had two different treatments for metastatic bowel cancer. The trial began in late 2020. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Related Products of 65-71-4
The Article related to trifluridine tipiracil bevacizumab third management metastatic colorectal cancer sunlight, ftd/tpi, phase iii, bevacizumab, metastatic colorectal cancer, randomized controlled trial, refractory, third line, trifluridine/tipiracil and other aspects.Related Products of 65-71-4
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia